SG11202100818RA - Tlr7/8 antagonists and uses thereof - Google Patents
Tlr7/8 antagonists and uses thereofInfo
- Publication number
- SG11202100818RA SG11202100818RA SG11202100818RA SG11202100818RA SG11202100818RA SG 11202100818R A SG11202100818R A SG 11202100818RA SG 11202100818R A SG11202100818R A SG 11202100818RA SG 11202100818R A SG11202100818R A SG 11202100818RA SG 11202100818R A SG11202100818R A SG 11202100818RA
- Authority
- SG
- Singapore
- Prior art keywords
- tlr7
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712439P | 2018-07-31 | 2018-07-31 | |
PCT/EP2019/070312 WO2020025517A1 (en) | 2018-07-31 | 2019-07-29 | Tlr7/8 antagonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100818RA true SG11202100818RA (en) | 2021-02-25 |
Family
ID=67660056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100818RA SG11202100818RA (en) | 2018-07-31 | 2019-07-29 | Tlr7/8 antagonists and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210300940A1 (zh) |
EP (1) | EP3830080A1 (zh) |
JP (1) | JP2021533125A (zh) |
KR (1) | KR20210040085A (zh) |
CN (1) | CN112513024A (zh) |
AU (1) | AU2019313441A1 (zh) |
BR (2) | BR122023023308A2 (zh) |
CA (1) | CA3108099A1 (zh) |
IL (1) | IL280479A (zh) |
MX (1) | MX2021000093A (zh) |
SG (1) | SG11202100818RA (zh) |
TW (1) | TWI827641B (zh) |
WO (1) | WO2020025517A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180094939A (ko) | 2015-12-17 | 2018-08-24 | 메르크 파텐트 게엠베하 | 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도 |
SG11201900947RA (en) | 2016-08-08 | 2019-02-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
BR112020012329A2 (pt) * | 2017-12-19 | 2020-11-24 | Merck Patent Gmbh | antagonistas de tlr7/8 e usos dos mesmos |
JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用 |
EP3950059A4 (en) * | 2019-03-29 | 2023-01-11 | Nippon Chemiphar Co., Ltd. | USE OF T-TYPE CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF PRURITIS |
US20220395496A1 (en) * | 2019-09-16 | 2022-12-15 | Hoffmann-La Roche Inc. | Piperidinyl amine compounds for the treatment of autoimmune disease |
TW202200139A (zh) * | 2020-05-14 | 2022-01-01 | 德商馬克專利公司 | 用於治療冠狀病毒感染之tlr7/8拮抗劑 |
AR124379A1 (es) | 2020-12-17 | 2023-03-22 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas |
CA3214808A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105636945B (zh) * | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
CN104557913B (zh) * | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物,其制备方法和用途 |
EP3317265A4 (en) * | 2015-07-01 | 2019-04-17 | Northwestern University | SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY |
WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
KR20180094939A (ko) | 2015-12-17 | 2018-08-24 | 메르크 파텐트 게엠베하 | 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도 |
CN106632089B (zh) * | 2016-11-04 | 2019-06-18 | 中山大学 | 一类喹唑啉类化合物及其制备方法与应用 |
-
2019
- 2019-07-29 AU AU2019313441A patent/AU2019313441A1/en active Pending
- 2019-07-29 CN CN201980051004.3A patent/CN112513024A/zh active Pending
- 2019-07-29 KR KR1020217005440A patent/KR20210040085A/ko not_active Application Discontinuation
- 2019-07-29 EP EP19755290.4A patent/EP3830080A1/en active Pending
- 2019-07-29 SG SG11202100818RA patent/SG11202100818RA/en unknown
- 2019-07-29 MX MX2021000093A patent/MX2021000093A/es unknown
- 2019-07-29 BR BR122023023308-5A patent/BR122023023308A2/pt unknown
- 2019-07-29 JP JP2021505638A patent/JP2021533125A/ja active Pending
- 2019-07-29 BR BR112021001618-0A patent/BR112021001618A2/pt unknown
- 2019-07-29 WO PCT/EP2019/070312 patent/WO2020025517A1/en unknown
- 2019-07-29 US US17/250,489 patent/US20210300940A1/en active Pending
- 2019-07-29 CA CA3108099A patent/CA3108099A1/en active Pending
- 2019-07-30 TW TW108126963A patent/TWI827641B/zh active
-
2021
- 2021-01-28 IL IL280479A patent/IL280479A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210040085A (ko) | 2021-04-12 |
CN112513024A (zh) | 2021-03-16 |
CA3108099A1 (en) | 2020-02-06 |
JP2021533125A (ja) | 2021-12-02 |
US20210300940A1 (en) | 2021-09-30 |
IL280479A (en) | 2021-03-01 |
TW202019899A (zh) | 2020-06-01 |
BR112021001618A2 (pt) | 2021-04-27 |
AU2019313441A1 (en) | 2021-03-18 |
TWI827641B (zh) | 2024-01-01 |
WO2020025517A1 (en) | 2020-02-06 |
MX2021000093A (es) | 2021-03-25 |
EP3830080A1 (en) | 2021-06-09 |
BR122023023308A2 (pt) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275463A (en) | TLR7/8 antagonists and their use | |
SG11202100818RA (en) | Tlr7/8 antagonists and uses thereof | |
IL264676B (en) | tlr 7/8 antagonists and their use | |
IL279897A (en) | Fusosome preparations and their uses | |
SG11202011015QA (en) | Fusosome compositions and uses thereof | |
IL291244A (en) | hpk1 antagonists and uses thereof | |
IL272016B (en) | Pyrrolidine history and their use as tlr7/8 antagonists | |
IL279755A (en) | Senolytic preparations and their uses | |
IL274751A (en) | ILDR2 antagonists and combinations thereof | |
IL292692A (en) | mrgprx2 antagonists and their uses | |
IL277663A (en) | Arunumab preparations and their uses | |
GB201807576D0 (en) | Compositions and uses thereof | |
IL289531A (en) | cd38 binding agents and uses thereof | |
IL288828A (en) | Binding factors - cd38 and their use | |
IL280369A (en) | New myokines and uses thereof | |
GB201821138D0 (en) | Compositions and uses thereof | |
SG11202009242RA (en) | Short conjugated oligoelectrolytes and uses thereof | |
GB201812334D0 (en) | Compositions and uses thereof | |
IL292693A (en) | mrgprx2 antagonists and their uses | |
GB201821144D0 (en) | Compositions and uses thereof | |
GB201815546D0 (en) | Composition and uses thereof | |
GB201819493D0 (en) | Compositions and uses thereof | |
GB201818495D0 (en) | Compositions and uses thereof | |
GB201818375D0 (en) | Compositions and uses thereof | |
GB201816605D0 (en) | New formulations and uses thereof |